Seaport Therapeutics
Boston, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $100M
Overview
Developing next-generation neuropsychiatric drugs by re-engineering existing pharmacophores for improved properties.
NeurosciencePsychiatry
Technology Platform
Chemistry platform specializing in pharmacophore re-engineering and prodrug design to optimize pharmacokinetics and brain delivery of neuroactive compounds.
Funding History
1Total raised:$100M
Series A$100M
Opportunities
Addressing the massive unmet need in depression and anxiety with potentially faster-acting, better-tolerated versions of proven therapeutic approaches.
Risk Factors
Risk that optimized pharmacokinetics may not translate to meaningfully improved clinical outcomes over existing generic or branded drugs.
Competitive Landscape
Competes with large pharma and other biotechs in psychiatry, but its focus on improving known mechanisms offers a potentially derisked path to differentiation.